These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials). McCullough PA; Ballantyne CM; Sanganalmath SK; Langslet G; Baum SJ; Shah PK; Koren A; Mandel J; Davidson MH Am J Cardiol; 2018 Apr; 121(8):940-948. PubMed ID: 29472008 [TBL] [Abstract][Full Text] [Related]
6. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease. Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335 [TBL] [Abstract][Full Text] [Related]
7. Lipoprotein(a), cardiovascular disease, and contemporary management. Jacobson TA Mayo Clin Proc; 2013 Nov; 88(11):1294-311. PubMed ID: 24182706 [TBL] [Abstract][Full Text] [Related]
8. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease. Chan J; Rajalingam T; Fossella J; Zhou H; Eisenberg N; Roche-Nagle G Ann Vasc Surg; 2020 Nov; 69():197-205. PubMed ID: 32554202 [TBL] [Abstract][Full Text] [Related]
9. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up. Perez de Isla L; Alonso R; Watts GF; Mata N; Saltijeral Cerezo A; Muñiz O; Fuentes F; Diaz-Diaz JL; de Andrés R; Zambón D; Rubio-Marin P; Barba-Romero MA; Saenz P; Sanchez Muñoz-Torrero JF; Martinez-Faedo C; Miramontes-Gonzalez JP; Badimón L; Mata P; J Am Coll Cardiol; 2016 Mar; 67(11):1278-85. PubMed ID: 26988947 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia. Avellone G; Di Garbo V; Guarnotta V; Scaglione R; Parrinello G; Purpura L; Torres D; Campisi D Int Angiol; 2010 Dec; 29(6):514-24. PubMed ID: 21173733 [TBL] [Abstract][Full Text] [Related]
11. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. Jellinger PS; Handelsman Y; Rosenblit PD; Bloomgarden ZT; Fonseca VA; Garber AJ; Grunberger G; Guerin CK; Bell DSH; Mechanick JI; Pessah-Pollack R; Wyne K; Smith D; Brinton EA; Fazio S; Davidson M Endocr Pract; 2017 Apr; 23(Suppl 2):1-87. PubMed ID: 28437620 [TBL] [Abstract][Full Text] [Related]
12. In pediatric familial hypercholesterolemia, lipoprotein(a) is more predictive than LDL-C for early onset of cardiovascular disease in family members. Zawacki AW; Dodge A; Woo KM; Ralphe JC; Peterson AL J Clin Lipidol; 2018; 12(6):1445-1451. PubMed ID: 30150142 [TBL] [Abstract][Full Text] [Related]
14. LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: Minority at target despite large reductions in LDL-C. van Delden XM; Huijgen R; Wolmarans KH; Brice BC; Barron JK; Blom DJ; Marais AD Atherosclerosis; 2018 Oct; 277():327-333. PubMed ID: 30270067 [TBL] [Abstract][Full Text] [Related]
15. Long term follow-up of genetically confirmed patients with familial hypercholesterolemia treated with first and second-generation statins and then with PCSK9 monoclonal antibodies. Pasta A; Cremonini AL; Formisano E; Fresa R; Bertolini S; Pisciotta L Atherosclerosis; 2020 Sep; 308():6-14. PubMed ID: 32771803 [TBL] [Abstract][Full Text] [Related]
16. Relation of First and Total Recurrent Atherosclerotic Cardiovascular Disease Events to Increased Lipoprotein(a) Levels Among Statin Treated Adults With Cardiovascular Disease. Wong ND; Zhao Y; Sung J; Browne A Am J Cardiol; 2021 Apr; 145():12-17. PubMed ID: 33454339 [TBL] [Abstract][Full Text] [Related]
17. Equivalent Impact of Elevated Lipoprotein(a) and Familial Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease. Hedegaard BS; Bork CS; Kaltoft M; Klausen IC; Schmidt EB; Kamstrup PR; Langsted A; Nordestgaard BG J Am Coll Cardiol; 2022 Nov; 80(21):1998-2010. PubMed ID: 36396201 [TBL] [Abstract][Full Text] [Related]
18. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control. Vallejo-Vaz AJ; Ray KK; Ginsberg HN; Davidson MH; Eckel RH; Lee LV; Bessac L; Pordy R; Letierce A; Cannon CP Atherosclerosis; 2019 Sep; 288():85-93. PubMed ID: 31349086 [TBL] [Abstract][Full Text] [Related]
19. Clinical Features and Gaps in the Management of Probable Familial Hypercholesterolemia and Cardiovascular Disease. Zafrir B; Jubran A; Lavie G; Halon DA; Flugelman MY; Shapira C Circ J; 2017 Dec; 82(1):218-223. PubMed ID: 28701632 [TBL] [Abstract][Full Text] [Related]
20. Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials. Ray KK; Vallejo-Vaz AJ; Ginsberg HN; Davidson MH; Louie MJ; Bujas-Bobanovic M; Minini P; Eckel RH; Cannon CP Atherosclerosis; 2019 Sep; 288():194-202. PubMed ID: 31253441 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]